The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. This report contains certain forward-looking statements that are based on the beliefs of management as well as assumptions made by and information currently available to management. The statements contained in this report relating to matters that are not historical facts are forward-looking statements that involve risks and uncertainties, including, but not limited to, future demand for our products and services, the successful commercialization of our products, general domestic and global economic conditions, government and environmental regulations, competition and customer strategies, changes in our business strategy or development plans, capital deployment, business disruptions, including those caused by fires, raw material supplies, technical failures, environmental regulations, and other risks and uncertainties, certain of which are beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those forward-looking statements set forth herein. When used in this report, the words "anticipate", "believe", "estimate" or "expect" or words of similar import are intended to identify forward-looking statements. For further discussion of certain of the matters described above and other risks and uncertainties, see "Risk Factors" in Item 1A of this annual report.

Undue reliance should not be placed on our forward-looking statements. Except as required by law, we disclaim any obligation to update any factors or to publicly announce the results of any revisions to any of the forward-looking statements contained in this annual report on Form 10-K to reflect new information, future events or other developments.

The following discussion and analysis should be read in conjunction with the accompanying Consolidated Financial Statements and Notes thereto appearing elsewhere in this Form 10-K.





Impact of COVID-19 Outbreak

Subsequent to year-end 2019, the World Health Organization declared a novel coronavirus (COVID-19) outbreak as a public health emergency. There have been mandates from international, federal, state and local authorities requiring forced closures of various businesses, schools and other facilities and organizations. While the closures and limitations on movement, domestically and internationally, are expected to be temporary, if the outbreak continues on its current trajectory the duration of the supply chain disruption could reduce the availability, or result in delays, of material or supplies to or from the Company, which in turn could materially interrupt the Company's business operations. Given the speed and frequency of continuously evolving developments with respect to this pandemic, the Company cannot reasonably estimate the magnitude of the impacts to its results of operations.





                                       13

--------------------------------------------------------------------------------


  Table of Contents



Overall Business Strategy

CurAegis Technologies, Inc. ("CurAegis", "the Company") was incorporated as a New York business corporation in September 1996 under the name Torvec, Inc. The Company's name was changed to CurAegis Technologies, Inc. in 2016 in connection with the establishment of its two business divisions. The CURA (Circadian User Risk Assessment) division is engaged in the fatigue management business and the Aegis division is engaged in the power and hydraulic business.

The Company develops and markets advanced technologies in the areas of safety, wellness and power. The Company is focused on the commercialization of a wellness and safety system (the myCadian system) and a uniquely designed hydraulic pump that will be smaller, lighter, less expensive and more efficient than current technology. The Company has not had significant revenue-producing operations.

It is important to note, regarding both the CURA and Aegis products, that the cycle time from the initiation of the sales process to revenue realization can be highly variable especially as a start-up entity. In addition to the activities to be undertaken to implement our plan of operations, we may expand and/or refocus our activities depending upon future circumstances and developments.

CURA Division: the myCadian system

The Company's CURA division has developed a proprietary technology designed to (i) measure the decrease in a person's alertness and (ii) to train individuals on how to improve alertness levels. The myCadian system will enable the user to anticipate and avert undesired or disastrous situations caused by the degradation of alertness. With the information provided from the myCadian software analytics, employees can work with Z-Coach our proprietary sleep training and education solution to correct sleep issues and improve overall wellness.

The myCadian platform is designed to predict and detect a degradation of alertness in a user. The myCadian platform will support multiple wearable technology including IOS and android devices. The myCadian system will include:



  ? a risk assessment that identifies the degradation of alertness that may affect
    a wearer's ability to perform tasks,
  ? real-time reporting that distills complex user data into actionable
    information on mobile devices,
  ? predictive reporting for a user to take action when alertness begins to wane,
    before fatigue becomes dangerous,
  ? flexible settings to provide employers a customized tool using their defined
    safety criteria and to create protocols for action,
  ? pricing that makes it affordable across a broad-based workforce, and
  ? the Z-Coach wellness program.



The Z-Coach wellness program is a key component of the myCadian system. Z-Coach learning topics include: Risks and Costs of Fatigue, Fundamentals of Sleep, Fatigue Mitigation and Countermeasures. Z-Coach participants gain an awareness of the dangers inherent in the lack of sleep and learn to utilize lifestyle tools to make changes to improve their health, mood, productivity and safety.

Aegis Division: Hydraulic Pump

During 2019, the Company initiated discussions with investment bankers and certain hydraulics companies to evaluate the possible monetization of the AEGIS technologies. Management believes these technologies have the potential to fundamentally shift the design and manufacture of future products in the hydraulics pump and motor industries.

The Aegis hydraulic pump technology has been designed to bring to the marketplace a unique concept in hydraulic pumps and motors that will be:



  ? smaller, lighter and less expensive than conventional pumps and motors,


  ? more efficient, and


   ? unique in its ability to scale larger, allowing more powerful pumps and motors.



The Company has completed a production prototype and is working to align the prototype capability with specific customer applications. The Company achieved significant milestones in the design and testing of this prototype. Engineering testing and design of the pump and motor functionality is continuing. Our engineering team has progressively made adjustments to traditional valve and piston technologies which have resulted in improvement in the measured efficiency of the pump. We have filed for patent protection for our novel non-rotating group pump concept and continue to file patents as a engineering breakthroughs in our design are identified.

In addition to the activities to be undertaken to implement our plan of operation detailed above, we may expand and/or refocus our marketing activities depending upon future circumstances and developments. Information regarding the Company and all of our inventions, including regular updates on technological and business developments, can be found on our website, www.CurAegis.com. The website and its contents are not incorporated by reference into this report.





                                       14

--------------------------------------------------------------------------------

Table of Contents

Results of Operations for the years ended December 31, 2019 and 2018

Revenue, Cost of Revenue and Loss on Revenue





                               For the year ended
                                  December 31,             Variance
                               2019          2018         Incr (decr)
CURA revenue                 $  15,000     $  37,000     $     (22,000 )
Cost of revenue                 13,000       110,000           (97,000 )
Earnings (loss) on revenue   $   2,000     $ (73,000 )   $      75,000

The Company recorded $15,000 and $37,000 in CURA revenue during the years ended December 31, 2019 and 2018, respectively. Revenue from Z-Coach stand-alone sales aggregated $13,000 and $26,000 for the years ended December 31, 2019 and 2018, respectively. During the year ended December 31, 2018, the Company recognized $11,000 in revenue from sales of the CURA system.

During the year ended December 31, 2019, fifty-one Z-Coach Aviation subscriptions were sold to five customers resulting in total customer sales of $7,000. As of December 31, 2019, and December 31, 2018, the Company has deferred revenue of $4,000 and $9,000, respectively attributed to Z-Coach subscription revenue that will be recognized ratably as our performance obligations are satisfied.

The Company recorded $13,000 and $110,000 in cost of revenue during the years ended December 31, 2019 and December 31, 2018, respectively. The cost of revenue includes software amortization and hosting fees incurred to provide the Z-Coach product to subscribers. Software amortization is based upon the straight-line amortization of the capitalized software over an estimated useful life of 36 months. The Z-Coach software was fully amortized in 2019.

The Z-Coach modules have been designed for a range of industry professionals, including aviation, trucking and busing industry and for corporate workers. The Z-Coach training module provides fatigue safety training over a twelve-month subscription period. The user has unlimited access to this tool during the subscription period. Customers are billed at the acceptance of the subscription and revenue is recognized ratably over the subscription period as our performance obligations are satisfied and when collection is reasonably assured.

Engineering and Development Costs and Expenses





                                       For the year ended
                                          December 31,              Variance
                                      2019           2018          Incr (decr)
Wages and benefits                  $ 502,000     $   731,000     $    (229,000 )
Professional fee and advisors         242,000         305,000           (63,000 )
Parts and shop supplies                12,000         102,000           (90,000 )
Computer and software maintenance      13,000          45,000           (32,000 )
Depreciation and amortization          22,000          38,000           (16,000 )
Other costs and expenses               11,000          11,000                 -
                                      802,000       1,232,000          (430,000 )
Stock based compensation                7,000          30,000           (23,000 )

Total Engineering and Development $ 809,000 $ 1,262,000 $ (453,000 )

Engineering and development expenses decreased during the year ended December 31, 2019 compared to the year ended December 31, 2018 due to: decrease in wages, professional fees and reduced spending for parts and shop supplies. Reduced headcount effected computer and software expenses reflecting reduction in number of subscription-based software programs. These decreases reflect reduced spending as a result of more focused engineering efforts as the Company gets closer to product commercialization. Engineering headcount was two and six professionals as of December 31, 2019 and 2018, respectively.





                                       15

--------------------------------------------------------------------------------

Table of Contents

General and Administrative Costs and Expenses





                                        For the year ended
                                           December 31,               Variance
                                       2019            2018          Incr (decr)
Wages and benefits                  $   838,000     $ 1,195,000     $    (357,000 )
Professional fees and advisors          210,000         199,000            11,000
Facilities and occupancy                137,000         153,000           (16,000 )
Insurance                                87,000          87,000                 -
Sales and marketing                      62,000          30,000            32,000
Patents                                  45,000         150,000          (105,000 )
Travel                                   31,000          44,000           (13,000 )
Computer and software maintenance        29,000          37,000            (8,000 )
Shareholder                              36,000          53,000           (17,000 )
Depreciation and amortization             2,000           8,000            (6,000 )
Other costs and expenses                 40,000          53,000           (13,000 )
                                      1,517,000       2,009,000          (492,000 )
Stock based compensation                119,000         150,000           (31,000 )

Total General and Administrative $ 1,636,000 $ 2,159,000 $ (523,000 )

General and administrative expense decreased during the year ended December 31, 2019 compared to the year ended December 31, 2018 primarily due to: headcount decreases in our sales and operations teams and reduced spending for patent costs. General and administrative headcount was five and nine at December 31, 2019 and 2018, respectively.

Provision for Inventory and Impairment Loss

The Company recorded a provision for excess inventory during the year ended December 31, 2018 based on changes in customer demand and technology developments. Inventory on hand at December 31, 2019 and December 31, 2018 has been fully reserved. The Company recognized $15,000 as a recovery of previously reserved inventory items upon the sale of certain of these components during the year ended December 31, 2019.

During the year ended December 31, 2018, the Company recorded an impairment charge of $17,000 on certain property and equipment that was no longer of use in the Company's product development.





Non-operating Expense



                          For the year ended
                             December 31,               Variance
                         2019             2018         Incr/decr
Interest expense     $ (1,233,000 )   $ (1,057,000 )   $  176,000
Debt issuance cost       (333,000 )              -        333,000
Vendor penalty           (300,000 )              -        300,000
Other income               18,000            1,000        (17,000 )
                     $ (1,848,000 )   $ (1,056,000 )   $  792,000

Interest expense increased by $176,000 for the year ended December 31, 2019 compared to the prior year. The Company has $10,310,000 in face value of convertible notes outstanding compared to $9,160,000 at December 31, 2018. During the year ended December 31, 2019, the Company recognized $1,233,000 in interest expense on the convertible, demand and promissory notes which includes $748,000 of amortization on debt discount that is classified as interest expense.

The increase in interest expense since 2018 reflects $650,000 of new 2019 convertible notes with an interest rate of 6% per annum issued since 2018, interest on $650,000 of demand notes with an interest rate of 6% per annum issued in the third quarter of 2019, and amortization of debt discount on July 2018 notes issued in the first half of 2019. The 2019 interest expense also reflects the interest incurred on the 6% unsecured promissory notes.

During 2019, the Company and the third-party vendor agreed to a $300,000 penalty payable to the vendor to reflect the aging on this outstanding liability.

During the year ended December 31, 2018 the Company recognized $1,057,000 in interest expense on the convertible notes including $627,000 of amortization on debt discount classified as interest expense related to the convertible notes.

Net Loss for the years ended December 31, 2019 and 2018

The net loss for the year ended December 31, 2019 was $4,276,000, compared with a net loss in the year ended December 31, 2018 of $6,308,000. The net loss attributable to common stockholders for the year ended December 31, 2019 was $4,494,000 as compared to $6,526,000 for the year ended December 31, 2018. The weighted average basic and diluted common shares outstanding amounted to 50,601,000 and 49,781,000 for each of the years ended December 31, 2019 and 2018, respectively. Basic and diluted loss per common share for each of the years ended December 31, 2019 and 2018 were $0.09 and $0.13 respectively.

Preferred stock dividends of $218,000 were recorded in the years ended December 31, 2019 and December 31, 2018.

Liquidity and Capital Resources

During the year ended December 31, 2019 we used $2,260,000 of cash in operating activities. A net loss of $4,276,000 was adjusted for $1,326,000 in non-cash expenses for: amortization of debt discount, depreciation and amortization, the non-cash expense recognized for the fair market value of share rights issued with demand notes, stock-based compensation and interest paid in common shares during the year. The Company reported $690,000 in changes in working capital components during the year ended December 31, 2019. The decrease in cash used in operations in the year ended December 31, 2019 compared to the year ended December 31, 2018 was driven primarily by the decrease in the net loss and the provision for inventory reserve taken in 2018.





                                       16

--------------------------------------------------------------------------------

Table of Contents

During the year ended December 31, 2019, the Company received net proceeds of $925,000 in senior convertible debt, $650,000 in demand notes and $800,000 in unsecured subordinated promissory notes. The Company repaid $150,000 in unsecured promissory notes during the third quarter of 2019 resulting in $2,225,000 in net cash provided by financing activities.

During the year ended December 31, 2018 we used $3,530,000 of cash in operating activities. A net loss of $6,308,000 was adjusted for $2,784,000 in non-cash expenses for: amortization of debt discount, depreciation and amortization, stock-based compensation, a reserve for inventory and an asset impairment, and interest paid in common shares during the year. The Company reported $6,000 in changes in working capital components during the year ended December 31, 2018. During the year ended December 31, 2018, the Company received net proceeds of $3,388,000 in senior convertible debt and $1,000 in proceeds from the exercise of a common stock warrant.

Current Cash Outlook and Management Plans

As of December 31, 2019, we have cash on hand of $18,000, negative working capital of $4,545,000, a stockholders' deficiency of $12,203,000 and an accumulated deficit of $91,425,000. During the year ended December 31, 2019 we raised $2,375,000 in proceeds through the issuance of demand notes, convertible notes and promissory notes. The proceeds from these private placements have been used to support the ongoing development and marketing of our core technologies and product initiatives.

Management estimates that the 2020 cash needs will be approximately $1.5 to 2 million, based upon the cash used in operations in the fourth quarter of 2019. As of December 31, 2019, the Company's cash on hand is not sufficient to cover the Company's future working capital requirements. This raises substantial doubt as to the Company's ability to continue as a going concern. Management continues to use its best efforts to develop financing opportunities to fund the development and commercialization of the CURA and Aegis products.

Since inception, we have financed our operations by the sale of our securities and debt financings. We need to raise additional funds to meet our working capital needs, to fund expansion of our business, to complete development, testing and marketing of our products, or to make strategic acquisitions or investments. No assurance can be given that necessary funds will be available for us to finance our development on acceptable terms, if at all. Furthermore, such additional financings will involve dilution to our shareholders or may require that we relinquish rights to certain of our technologies or products. In addition, we will experience operational difficulties and delays due to working capital restrictions. If adequate funds are not available from additional sources of financing, we will have to delay or scale back our growth plans.

The Company's ability to fund its current and future commitments from its available cash depends on a number of factors. These factors include the Company's ability to (i) launch and generate sales from the CURA products or (ii) generate proceeds from the monetization of our hydraulic technologies. If these and other factors are not met, the Company would need to raise funds in order to meet its working capital needs and pursue its growth strategy. Although there can be no such assurances, management believes that sources for these additional funds will be available through either current or future investors.

Critical Accounting Policies

Revenue Recognition

The Company has two sources of revenue: (i) from the sale of CURA products and (ii) from stand-alone Z-Coach subscriptions. Revenue from the sale of CURA products is recognized upon the shipment to a customer and upon the company's satisfaction of all performance obligations as described in customer agreements. The Z-Coach Program provides fatigue training over an annual subscription period of twelve months. The Z-Coach Program allows the user unlimited access during the annual subscription period. Customers are billed at the acceptance of the subscription, and revenue is recognized ratably over the subscription period as our performance obligations are satisfied and when collection is reasonably assured. Our collection terms provide customers standard terms of net 30 days. Future performance obligations are reflected in deferred revenue.

Income Taxes

We account for income taxes using the asset and liability method, the objective of which is to establish deferred tax assets and liabilities for the temporary differences between the financial reporting and the tax basis of our assets and liabilities at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized.

We account for uncertain tax positions using a more-likely-than-not recognition threshold based on the technical merits of the tax position taken. Tax benefits that meet the more-likely-than-not recognition threshold should be measured as the largest amount of tax benefits, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement in the financial statements. It is our policy to recognize interest and penalties related to income tax matters as general and administrative expenses. As of December 31, 2019 and December 31, 2018, there were no accrued interest or penalties related to uncertain tax positions.





                                       17

--------------------------------------------------------------------------------


  Table of Contents



Stock-Based Compensation

FASB ASC 718-10 requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the requisite service period (generally the vesting period) in the consolidated financial statements based on their fair values on the grant date. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount recognized. In addition, the realization of tax benefits in excess of amounts recognized for financial reporting purposes will be recognized as a financing activity in accordance with FASB ASC 718-10.

No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for substantially all net deferred tax assets.

FASB ASC 505-50, "Equity-Based Payments to Non-Employees," requires all share-based payments to non-employees, including grants of stock options, to be recognized in the consolidated financial statements as compensation expense over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black-Scholes valuation model, we periodically reassess the fair value of non-employee options as service conditions are met, which generally aligns with the vesting period of the options, and we adjust the expense recognized in the consolidated financial statements accordingly.

FASB ASC 718-20 requires that modifications of the terms or conditions of equity awards be treated as an exchange of the original award for a new award. Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified.

Impact of Inflation

Inflation has not had a significant impact on our operations to date and we are currently unable to determine the extent inflation may impact our operations in future periods.





Quarterly Fluctuations

Since we are currently focused on developing our technologies for commercialization and we have not yet engaged in significant revenue producing operations, we do not have any meaningful quarterly fluctuations that impact our financial performance.

© Edgar Online, source Glimpses